Is 261280558 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 261280558 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 261280558 ($18.3) is trading below our estimate of fair value ($41.31)
Significantly Below Fair Value: 261280558 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 261280558?
Key metric: As 261280558 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 261280558. This is calculated by dividing 261280558's market cap by their current
earnings.
What is 261280558's PE Ratio?
PE Ratio
106.6x
Earnings
NT$1.85b
Market Cap
NT$196.72b
261280558 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
21.3x
Enterprise Value/EBITDA
151x
PEG Ratio
1.2x
Price to Earnings Ratio vs Peers
How does 261280558's PE Ratio compare to its peers?
Price-To-Earnings vs Industry: 261280558 is expensive based on its Price-To-Earnings Ratio (106.6x) compared to the European Biotechs industry average (28.1x).
Price to Earnings Ratio vs Fair Ratio
What is 261280558's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
261280558 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
106.6x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 261280558's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.